Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 8—August 2025
Dispatch
Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016–2023
, Jeremy A.W. Gold, Kaitlin Forsberg, Sophie Jones, and Meghan M. Lyman
Table 1
Characteristics of patients with Candida auris screening cases with and without progression to clinical case status, United States, 2016–2023*
| Characteristic | All, N = 21,195 | With clinical case, n = 1,458 | Without clinical case, n = 19,737 | p value† |
|---|---|---|---|---|
| Median age at collection of screening case specimen, y (IQR), n = 17,928 |
68 (58–76) |
67 (59–76) |
68 (58–77) |
0.650 |
| Age group at collection of screening case specimen, y, n = 17,928 | 0.113 | |||
| <45 | 1,738 | 118 (6.8) | 1,620 (93.2) | |
| 45–54 | 1,778 | 105 (5.9) | 1,673 (94.1) | |
| 55–64 | 3,725 | 279 (7.5) | 3,446 (92.5) | |
| 65–74 | 5,239 | 368 (7.0) | 4,871 (93.0) | |
| 75–84 | 3,808 | 274 (7.2) | 3,534 (92.8) | |
| >85 |
1,640 |
94 (5.7) |
1,546 (94.3) |
|
| Sex, n = 16,446 | 0.478 | |||
| M | 9,448 | 668 (7.1) | 8,780 (92.9) | |
| F |
6,998 |
515 (7.4) |
6,483 (92.6) |
|
| Antimicrobial Resistance Laboratory Network region of the facility of collection for screening case specimen‡ | <0.001 | |||
| West | 6,617 | 898 (13.6) | 5,719 (86.4) | |
| Midwest | 4,264 | 96 (2.3) | 4,168 (97.7) | |
| Southeast | 4,235 | 56 (1.3) | 4,179 (98.7) | |
| Northeast | 3,570 | 302 (8.5) | 3,268 (91.5) | |
| Mid-Atlantic | 1,484 | 64 (4.3) | 1,420 (95.7) | |
| Mountain | 977 | 42 (4.3) | 935 (95.7) | |
| Central |
48 |
0 |
48 (100.0) |
|
| Facility type of screening case specimen collection, n = 17,357 | <0.001 | |||
| Long-term acute care hospital | 8,716 | 907 (10.4) | 7,809 (89.6) | |
| Acute care hospital | 5,033 | 299 (5.9) | 4734 (94.1) | |
| Ventilator-equipped skilled nursing facility | 2,912 | 150 (5.2) | 2,762 (94.8) | |
| Skilled nursing facility | 490 | 13 (2.7) | 477 (97.3) | |
| Other¶ | 206 | 4 (1.9) | 202 (98.1) | |
*Values are no. (%) except as indicated. †p values were calculated using χ2 tests to compare characteristics of patients with a C. auris screening case who had (vs. did not have) progression to a C. auris clinical case. ‡From https://www.cdc.gov/antimicrobial-resistance-laboratory-networks/php/about/domestic.html. Data from 2023 were unavailable from 1 state in the Central region. ¶Includes those listed as other (n = 193), inpatient rehabilitation (n = 12), and outpatient (n = 1).